Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.

In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

In this systematic review, significant improvements in clinical severity, patient-reported outcomes, and quality of life were reported for dupilumab compared to placebo in patients with moderate-to-severe atopic dermatitis, prurigo nodularis, and alopecia areata, supporting its efficacy and safety for these dermatological conditions.

This study reports a case where a biologic medication used for atopic dermatitis unexpectedly also treated concurrent alopecia areata.

This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

This study observed that the choice between using Belimumab and Anifrolumab for treating active Systemic Lupus Erythematosus was mainly based on clinical phenotype, with Anifrolumab linked to chronic-active disease and Belimumab associated with relapsing-remitting disease.

This study observed that dupilumab may promote hair regrowth in alopecia areata patients, achieving significant results in a majority of cases without reported adverse events.

This article suggests considering biologics to stabilize inflammation in moderate to severe folliculitis decalvans, although it reports no new clinical results.

This study found that tralokinumab effectively reduced the severity of moderate-to-severe atopic dermatitis over 28 weeks in adults, with significant improvements in clinical outcomes and biological markers, although 27.4% of patients discontinued treatment due to adverse events or ineffectiveness.

In this retrospective study, dupilumab treatment in young children with alopecia areata and atopic features was linked to full hair regrowth without serious adverse events, though findings from this small cohort should be interpreted cautiously.

This study found that patients with systemic lupus erythematosus reported improvements in symptoms such as fatigue and joint pain after Anifrolumab treatment, with a corresponding decrease in corticosteroid use, although some disease impacts on daily life remained.

This case study reports significant improvement in severe atopic dermatitis and alopecia areata symptoms in a patient treated with dupilumab, highlighting the potential for patient selection in optimizing therapeutic outcomes.

This study explored the experiences of systemic lupus erythematosus patients receiving Anifrolumab, revealing improvements in self-reported symptoms and daily life impacts alongside decreased disease activity and lowered corticosteroid use.

This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.

In this study, adult hereditary angioedema patients treated with lanadelumab at a Spanish hospital had a 94.1% reduction in angioedema episodes and needed 61% less on-demand medication, showing improved quality of life and minimal adverse effects.

This study reports that dupilumab significantly reduced alopecia areata severity in pediatric patients with atopic dermatitis, indicating potential as an effective treatment option, though further research on long-term safety and optimal use is needed.

This study examined the market trends for biologics that have lost patent exclusivity and predicted that drugs like adalimumab, once facing competition, could see price reductions and decreased market share, although the impact on accessibility and total patient use remains unclear.

In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.

This case report describes a patient with Crohn's disease developing alopecia and psoriasiform skin lesions while on adalimumab treatment.

In this retrospective study, researchers found a statistically significant increase in the risk of alopecia areata among atopic dermatitis patients using dupilumab compared to controls, suggesting the need for careful monitoring and further research on the drug's impact on alopecia areata.

This study found that dupilumab treatment in alopecia areata significantly suppressed Th2-related markers and increased hair keratin levels, suggesting a potential role of Th2 cytokines in the disease's pathogenesis.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

In this study, a patient with severe alopecia areata showed significant hair regrowth after 15 months of partial response to baricitinib and oral minoxidil, following the addition of dupilumab to their treatment regimen.